- Home
- MGRX vs KPRX Comparison
MGRX vs KPRX Comparison
Compare MGRX & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGRX
- KPRX
- Stock Information
- Founded
- MGRX 2021
- KPRX 1998
- Country
- MGRX United States
- KPRX United States
- Employees
- MGRX N/A
- KPRX N/A
- Industry
- MGRX Computer Software: Prepackaged Software
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- MGRX Technology
- KPRX Health Care
- Exchange
- MGRX Nasdaq
- KPRX Nasdaq
- Market Cap
- MGRX 8.1M
- KPRX 8.3M
- IPO Year
- MGRX 2023
- KPRX N/A
- Fundamental
- Price
- MGRX $1.38
- KPRX $3.13
- Analyst Decision
- MGRX
- KPRX Strong Buy
- Analyst Count
- MGRX 0
- KPRX 1
- Target Price
- MGRX N/A
- KPRX $10.00
- AVG Volume (30 Days)
- MGRX 434.6K
- KPRX 12.7K
- Earning Date
- MGRX 05-27-2025
- KPRX 05-09-2025
- Dividend Yield
- MGRX N/A
- KPRX N/A
- EPS Growth
- MGRX N/A
- KPRX N/A
- EPS
- MGRX N/A
- KPRX N/A
- Revenue
- MGRX $615,873.00
- KPRX $20,000.00
- Revenue This Year
- MGRX N/A
- KPRX N/A
- Revenue Next Year
- MGRX N/A
- KPRX N/A
- P/E Ratio
- MGRX N/A
- KPRX N/A
- Revenue Growth
- MGRX N/A
- KPRX N/A
- 52 Week Low
- MGRX $1.49
- KPRX $2.51
- 52 Week High
- MGRX $16.80
- KPRX $5.55
- Technical
- Relative Strength Index (RSI)
- MGRX 32.29
- KPRX 42.15
- Support Level
- MGRX $1.65
- KPRX $2.85
- Resistance Level
- MGRX $1.84
- KPRX $3.30
- Average True Range (ATR)
- MGRX 0.17
- KPRX 0.20
- MACD
- MGRX 0.02
- KPRX -0.02
- Stochastic Oscillator
- MGRX 4.62
- KPRX 16.34
About MGRX Mangoceuticals Inc.
Mangoceuticals Inc focuses on developing, marketing, and selling a variety of men's wellness products and services through a telemedicine platform. The company's platform provides access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations, including Mango ED products.
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.